1-3 of 3
Letizia Lupo
Close
Sort by
Journal Articles

Prefibrotic Myelofibrosis (PreMF) Belongs to a Continuum of Epidemiological, Clinical and Histological Characteristics Featuring Primary Myelofibrosis (PMF)

Giovanni Barosi, MD, Vittorio Rosti, MD, Rita Campanelli, Biol. Sci, Paolo Catarsi, PhD, Antonina M. Isgrò, Lab Tech, Letizia Lupo, MD, Margherita Massa, Ph D, Valentina Poletto, Biol Sci, Gianluca Viarengo, MD, Laura Villani, Biol Sci, Umberto Magrini, MD
Journal: Blood
Blood (2011) 118 (21): 1743.
https://doi.org/10.1182/blood.V118.21.1743.1743
Published: 2011
Journal Articles

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Clinical Trials & Observations
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Lorenzo Tozzi, Flavia Biamonte, Niccolò Bartalucci, Elisabetta Gattoni, Maria Letizia Lupo, Guido Finazzi, Alessandro Pancrazzi, Elisabetta Antonioli, Maria Chiara Susini, Lisa Pieri, Elisa Malevolti, Emilio Usala, Ubaldo Occhini, Alberto Grossi, Silvia Caglio, Simona Paratore, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi, on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators
Journal: Blood
Blood (2011) 118 (8): 2069–2076.
https://doi.org/10.1182/blood-2011-01-330563
Published: 2011
Includes: Supplemental data
Journal Articles

A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results

Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD, Letizia Lupo, MD, Maria Chiara Finazzi, MD, Lorenzo Tozzi, BiSc, Flavia Biamonte, BiSc, Arianna Masciulli, MD, Maria Chiara Susini, MD, Alessandro Pancrazzi, BiSc, Guido Finazzi, MD, Simona Paratore, MD, Roberto Marchioli, Alberto Bosi, Tiziano Barbui, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD
Journal: Blood
Blood (2010) 116 (21): 314.
https://doi.org/10.1182/blood.V116.21.314.314
Published: 2010